ERYTech: Stronger penetration of Oncaspar in the US. Positive read-across for GRASPA

BUY, Fair Value EUR42 (+45%)
News published on October Friday 30, 2015
Share on

Yesterday, Baxalta released its Q3 15 results, which now integrate the recently-completed Oncaspar (pegylated form of asparaginase) acquisition. Interestingly, Oncaspar sales are now “approaching an annual run rate of USD200m”. We think this is due to a deeper penetration of the different forms of asparaginases in the US, notably following the accumulation of studies demonstrating the superiority of asparaginase-based regimens in adults with Phi- ALL. This is quite positive for Erytech as: 1/ it shows that the penetration of the different forms of this therapeutic enzyme should increase in the coming years, and 2/ by expanding its reach to the frontline setting, GRASPA would benefit from these upward trends.

For more information, please contact  

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities